{"organizations": [], "uuid": "77c5bfc4b82429e230c248167f33f81f11bb2562", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-corbus-agrees-with-fda-on-phase-2b/brief-corbus-agrees-with-fda-on-phase-2b-cystic-fibrosis-study-design-with-pulmonary-exacerbations-as-sole-primary-endpoint-idUSFWN1PO12N", "country": "US", "domain_rank": 408, "title": "BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.981, "site_type": "news", "published": "2018-01-30T05:23:00.000+02:00", "replies_count": 0, "uuid": "77c5bfc4b82429e230c248167f33f81f11bb2562"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-corbus-agrees-with-fda-on-phase-2b/brief-corbus-agrees-with-fda-on-phase-2b-cystic-fibrosis-study-design-with-pulmonary-exacerbations-as-sole-primary-endpoint-idUSFWN1PO12N", "ord_in_thread": 0, "title": "BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "corbus pharmaceuticals holdings inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 29 (Reuters) - Corbus Pharmaceuticals Holdings Inc :\n* CORBUS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2B CYSTIC FIBROSIS STUDY DESIGN WITH PULMONARY EXACERBATIONS AS SOLE PRIMARY ENDPOINT\n* ‍FDA ALSO AGREED TO INCLUSION OF ADOLESCENTS 12-17 YEARS OF AGE ALONGSIDE ADULTS IN PHASE 2B STUDY​\n* ‍FIRST PATIENT EXPECTED TO BE DOSED IN THE QUARTER FOR PHASE 2B CYSTIC FIBROSIS STUDY​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-30T05:23:00.000+02:00", "crawled": "2018-01-30T19:08:02.001+02:00", "highlightTitle": ""}